参与者简介 实验室
Calico
Calico Life Sciences LLC
使命 : Harness advanced technologies to increase human healthspan.
AI生成的领域概念图，并非该机构或其设施的照片。
- 成立于
- 2013
- 总部
- San Francisco, California, USA
- 状态
- 活跃
研究与方法
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
部分旧有编辑内容仅有法文或英文版本。
研究方向
- Aging biology
- Drug discovery
- Senolytics
- Cellular reprogramming
- Biomarkers
发展与当前工作
这些早期里程碑未关联一手证据，仍需核实，不应视为已确认的承诺。
- 2025 · ABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
- 2026 · Combination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
- 2028 · Age reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
参与的生态系统
组织与相关资料
法律身份
- 法定名称
- Calico Life Sciences LLC
- 状态
- 活跃
- 核验日期
- 2026-08-30
- 下次复核
- 2026-11-30
来源与文献
每份参考资料均与其支持的论述关联。机构文献描述其自身工作，不构成独立验证。
- 01
- 02
Research
www.calicolabs.com